The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 38, Issue 2, 2012, Pages 228-235

  Kim, Sung Wan ^a   Yoon, Jin Sang ^a   Kim, Yong Sik ^b   Ahn, Yong Min ^b   Kim, Chul Eung ^c   Go, Hyo Jin ^d   Chee, Ik Seung ^e   Jung, Sung Won ^f   Chung, Young Chul ^g   Kim, Young Don ^h   Joe, Soohyun ⁱ   Lee, Jonghun ^j   Kwon, Young Joon ^k   Yoon, Bo Hyun ^l   Jae, Young Myo ^m  

^a Chonnam National University Medical School   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Inha University Hospital   (South Korea)

^d Daejeon St Mary's Hospital   (South Korea)

^e Chungnam National University College of Medicine   (South Korea)

^f Dongsan Medical Center   (South Korea)

^g Chonbuk National University Medical School   (South Korea)

^h Sun General Hospital   (South Korea)

ⁱ Bugok National Hospital   (South Korea)

^j Catholic University of Daegu   (South Korea)

^k Soonchunhyang University College of Medicine   (South Korea)

^l Naju National Hospital   (South Korea)

^m Bong Seng Memorial Hospital   (South Korea)

more..

Author keywords

Attitude toward medication; Paliperidone; Risperidone; Schizophrenia; Well being

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; HYPNOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZOLPIDEM;

ABDOMINAL DISCOMFORT; ADULT; AKATHISIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DIZZINESS; DRUG ATTITUDE INVENTORY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPROLACTINEMIA; INSOMNIA; KRAWIECKA SCALE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OLIGOMENORRHEA; OPEN STUDY; PARKINSONISM; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERSONAL AND SOCIAL PERFORMANCE SCALE; PREDICTION; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUBJECTIVE WELL BEING UNDER NEUROLEPTIC TREATMENT SCALE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION; WELLBEING;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PERSONAL SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84862880594     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.04.004     Document Type: Article

References (55)

1. Amador X.F., Flaum M., Andreasen N.C., Strauss D.H., Yale S.A., Clark S.C., et al. Awareness of illness in schizophrenia, schizoaffective and mood disorders. Arch Gen Psychiatry 1994, 51:826-836.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press Inc, Washington DC. 4th ed.
3. Canuso C.M., Youssef E.A., Bossie C.A., Turkoz I., Schreiner A., Simpson G.M. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008, 23:209-215.
4. Canuso C.M., Grinspan A., Kalali A., Damaraju C.V., Merriman U., Alphs L., et al. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol 2010, 25:155-164.
5. Conley R., Gupta S.K., Sathyan G. Clinical spectrum of the osmotic controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006, 22:1879-1892.
6. de Leon J., Wynn G., Sandson N.B. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010, 51:80-88.
7. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003, 416:16-23. [Suppl.].
8. Herings R.M., Erkens J.A. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003, 12:423-424.
9. Hogan T.P., Awad A.G. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992, 22:347-352.
10. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13:177-183.
11. Inada T., Yagi G., Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res 2002, 57:227-238.
12. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., et al. Randomized controlled trial of the effect on quality of life of second- versus first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006, 63:1079-1087.
13. Jung H.Y., Hwang S.S., Yi J.S., Kim Y., Kim Y.S. Clinician-rated functioning and patient-rated quality of life in schizophrenia: implications of their correspondence for psychopathology and side effects. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:225-230.
14. Kampman O., Laippala P., Vaananen J., Koivisto E., Kiviniemi P., Kilkku N., et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res 2002, 110:39-48.
15. Kapur S., Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001, 158:360-369.
16. Karow A., Moritz S., Lambert M., Schoder S., Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005, 38:320-326.
17. Karow A., Czekalla J., Dittmann R.W., Schacht A., Wagner T., Lambert M., et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 2007, 68:75-80.
18. Karow A., Pajonk F.G., Reimer J., Hirdes F., Osterwald C., Naber D., et al. The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life. Eur Arch Psychiatry Clin Neurosci 2008, 258:152-159.
19. Karow A, Naber D, Lambert M, Moritz S, on behalf of the EGOFORS initiative. Remission as perceived by people with schizophrenia, family members and psychiatrists. Eur Psychiatry in press.
20. Kim J.H., Jung H.Y., Kang U.G., Jeong S.H., Ahn Y.M., Byun H.J., et al. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders. Mov Disord 2002, 17:1354-1359.
21. Kim J.H., Cho S.Y., Byun H.J., Kang U.G., Ahn Y.M., Kim Y.S. Multidimensional sensory phenomena in antipsychotic-induced akathisia. J Clin Psychopharmacol 2004, 24:618-623.
22. Kim S.W., Yoon J.S., Choi S.K. Survey of medication adherence in patients with schizophrenia - Korean ADHES data. Hum Psychopharmacol 2006, 21:533-537.
23. Kim S.W., Shin I.S., Kim J.M., Yoo J.A., Ahn Y.M., Kwon J.S., et al. A validation study of the Korean version of Subjective Well-being under Neuroleptic Treatment Scale - short form. Korean J Psychopharmacol 2007, 18:221-230.
24. Kim S.W., Shin I.S., Kim J.M., Lee S.H., Lee Y.H., Yang S.J., et al. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Hum Psychopharmacol 2009, 24:565-573.
25. Krawiecka M., Goldberg D., Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 1977, 55:299-308.
26. Lambert M., Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004, 18(Suppl. 2):5-17.
27. Lambert M., Naber D., Eich F.X., Schacht M., Linden M., Schimmelmann B.G. Remission of severely impaired subjective well-being in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand 2007, 115:106-113.
28. Lambert M., Naber D., Schacht A., Wagner T., Huber C., Karow A., et al. Predicting remission and recovery in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand 2008, 118:220-229.
29. Lambert M., Naber D., Karow A., Huber C.G., Köhler J., Heymann J., et al. Subjective well-being under quetiapine treatment: effect of diagnosis, mood state, and anxiety. Schizophr Res 2009, 110:72-79.
30. Lee J.G., Seok J.H., Lee J.Y., Lee K.U., Kwak K.H., Kwon J.S., et al. A validation study of the Korean-Version of the Personal and Social Performance Scale. Korean J Psychopharmacol 2006, 17:497-506.
31. Lee S.Y., Sohn K.M., Ryu J.Y., Yoon Y.R., Shin J.G., Kim J.W. Sequence-based CYP2D6 genotyping in the Korean population. Ther Drug Monit 2006, 28:382-387.
32. Marder S.R. Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998, 59:21-25.
33. Marder S.R. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand 2005, 427:43-46. [Suppl.].
34. Masand P.S. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005, 7:121-129.
35. Moritz S., Krausz M., Gottwalz E., Lambert M., Perro C., Ganzer S., et al. Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics. Psychopathology 2000, 33:48-51.
36. Morosini P.L., Magliano L., Brambilla L., Ugolini S., Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000, 101:323-329.
37. Naber D. A self-rating to measure subjective effects of neuroleptic drug relationships to objective psychopathology, quality of life, compliance, and other clinical variables. Int Clin Psychopharmacol 1995, 10(Suppl. 3):133-138.
38. Naber D., Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol 2001, 11(Suppl. 4):S391-S396.
39. Naber D., Moritz S., Lambert M., Pajonk F.G., Holzbach R., Mass R., et al. Improvement of schizophrenic patients' subjective wellbeing under atypical antipsychotic drugs. Schizophr Res 2001, 50:79-88.
40. Naber D., Riedel M., Klimke A., Vorbach E.U., Lambert M., Kühn K.U., et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 2005, 111:106-115.
41. Pani L., Marchese G. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opin Drug Deliv 2009, 6:319-331.
42. Perkins D.O., Johnson J.L., Hamer R.M., Zipursky R.B., Keefe R.S., Centorrhino F., et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 2006, 83:53-63.
43. Razali M.S., Yahya H. Compliance with treatment in schizophrenia: a drug intervention program in a developing country. Acta Psychiatr Scand 1995, 91:331-335.
44. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999, 56:241-247.
45. Rossi A., Vita A., Tiradritti P., Romeo F. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol 2008, 23:216-222.
46. Schennach-Wolff R., Seemüller F., Obermeier M., Messer T., Laux G., Pfeiffer H., et al. Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders. Eur Psychiatry 2011, 26:284-292.
47. Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 2005, 162:1984-1985.
48. Shin H.Y., Kim S.W., Kim J.H., Chung Y.C., Chung I.W., Chee I.S., et al. The effects of olanzapine in the maintenance treatment of outpatients with schizophrenia and other psychotic disorders. Korean J Psychopharmacol 2006, 17:342-348.
49. Trennery M. Validation of a Scale to Predict Medication Compliance in Psychiatric Outpatients [doctoral thesis]. Vermillion: University of South Dakota. 1983.
50. Tsai J.K., Lin W.K., Lung F.W. Social Interaction and Drug Attitude Effectiveness in Patients with Schizophrenia. Psychiatr Q 2011, 82:343-351.
51. Valenstein M., Copeland L.A., Blow F.C., McCarthy J.F., Zeber J.E., Gillon L., et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002, 40:630-639.
52. Wehmeier P.M., Kluge M., Schacht A., Helsberg K., Schreiber W. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res 2007, 91:178-186.
53. Wehmeier P.M., Kluge M., Schneider E., Schacht A., Wagner T., Schreiber W. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 30:703-712.
54. Weiden P.J., Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995, 21:419-429.
55. Yoon B.H., Bahk W.M., Lee K.U., Hong C.H., Ahn J.K., Kim M.K. Psychometric properties of Korean version of Drug Attitude Inventory (KDAI-10). Korean J Psychopharmacol 2005, 16:480-487.